Three Pillars Must Support Value Added Medicines In EU
Medicines For Europe Wants To ‘Level The Playing Field’ With US
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.
You may also be interested in...
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.
Belgium’s recent royal decree on pharmaceutical reimbursement represents “three significant steps forward for the generic medicines sector”, according to local off-patent industry association FeBelGen. As well as simplifying reimbursement, the association points out, the decree also sets out a reimbursement pathway for value-added medicines as well as removing certain packaging requirements.